Please login to the form below

Not currently logged in
Email:
Password:

Biomarker

This page shows the latest Biomarker news and features for those working in and with pharma, biotech and healthcare.

FDA approves Roche’s Actemra COVID-19 trial

FDA approves Roche’s Actemra COVID-19 trial

Previous research has suggested that elevated IL-6 – a biomarker for inflammation and a high-level immune response – is associated with a higher mortality in people with community-acquired pneumonia.

Latest news

More from news
Approximately 5 fully matching, plus 306 partially matching documents found.

Latest Intelligence

  • The search for treatments for Parkinson’s disease The search for treatments for Parkinson’s disease

    Two years on, there is real conviction that transformative therapies, in the shape of disease-modifying drugs, gene therapy, growth factors, vaccines and repurposed drugs along with potential biomarkers offer a

  • Biopharma and orphan drugs Biopharma and orphan drugs

    It’s important to highlight that advances in personalised medicine have additional regulatory requirements, such as biomarker validation. ... The current biomarker qualification process lengthens already cumbersome procedures thus jeopardising access

  • GSK forges ahead with its dynamic COPD and asthma portfolio GSK forges ahead with its dynamic COPD and asthma portfolio

    The promise includes a vaccine, which will report on phase 2 trials later this year, continuing work to identify biomarkers, and the start of a phase 3 trial of its therapy ... The emergence of eosinophil counts as a biomarker in COPD has been helpful.

  • Alzheimer’s: the search for a cure Alzheimer’s: the search for a cure

    As important, the biomarker evidence supports the mechanism, with significant amyloid reduction leading to.

  • Putting commercial intelligence at the heart of strategy Putting commercial intelligence at the heart of strategy

    However, MSD went down a narrower clinical development path with detailed biomarker requirements that created hurdles for patient identification.

More from intelligence
Approximately 2 fully matching, plus 48 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 16 partially matching documents found.

Latest from PMHub

  • The ALS patient journey

    But firstly, patients will struggle to get a diagnosis. There isn’t a biomarker or a blood test, instead, you have to rule out other causes of your symptoms.

  • Life with multiple myeloma - why I'm a lucky man living the dream

    Apart from losing my hair, I felt relatively unscathed, unfortunately so did the myeloma, in fact my biomarkers went up. ... My biomarkers began falling to manageable levels and the lower toxicity of the drug meant I started to feel more normal again.

  • Diagnosing the lag in neuropsychiatric treatments

    The answer is simple, while bacterial and viral infections could be distinguished through characteristic biomarkers, reliable biomarkers for psychiatric diseases are almost non-existent.

  • Navigating the antibiotic resistance crisis

    Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians navigating this complex landscape.

  • Three key development areas in the management of multiple sclerosis

    Mark and Fabrice identified three key themes across the meeting:. The use of neurofilament light chain (NfL) levels as a biomarker for disease activity and response to treatment– when neurons or ... Research presented at ECTRIMS shows promise for NfL

More from PMHub
Approximately 5 fully matching, plus 14 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

DEMAND DIVERSITY REPORT 02: Why is the LGBTQ+ community facing poorer health outcomes due to COVID-19?
We’re all aware that clinical trials have been discussed more widely since the COVID-19 pandemic. While that’s a great thing for raising awareness of clinical trials in general, it’s also...
CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...

Infographics